IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Keith L. Black and Nagendra S. Ningaraj

Appln. No.

Continuation of 09/491,500

Filed

1 4

October 29, 2003

Examiner

Unassigned

Customer No.:

20786

Commissioner for Patents Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450

October 29, 2003

Transmittal of Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

This Transmittal is accompanied by a fee of \$180.00, for filing an Information Disclosure. However, if the Examiner determines no fee is required, the Commissioner is authorized to credit any overpayments or charge any additional fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,

Sherry M. Knowles, Esq.

Reg. No. 33,052

King & Spalding 191 Peachtree St. Atlanta, Georgia 30303 404-572-3541 404-572-5145 (fax) FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT (Use several sheets if necessary)

ATTY, DOCKET NO. 08143.105002			SERIAL NO.		FILING DATE October 29, 2003				
APPLICANT Keith L. Black and Nagendra S. Ningaraj				GROUP					
	100.0			U.S. PA	TENT DOCUM	ENTS		- 2-	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME			CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,518,499	05/21/06	Agar				·	
	AB	5,767,160	5,767,160 06/16/98 Kaeseme		eyer				
		OTHER P	REFERENC	CES (Inclu	ding Author, Title	e, Date, Pert	inent Pag	es, Etc.)	<i></i>
AC Armstead, W.M., Contribut Brain Res, 799:44-48 (1998				tion of kca channel activation to hypoxic cerebrovasodilation does not involve NO, 8). ABSTRACT ONLY.					
	AD	Barna, M., et al., Activation of type III nitric oxide synthase in astrocytes following a neurotropic viral infection, Virology, 223: 331-343 (1996).				irotropic viral			
	AĒ		Becker, E.M., et al., The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rate platelets, J Cardiovasc Pharmacol, 35(3):390-7 (2000). ABSTRACT ONLY.						
	AF	Boje, K.M., Inhibition of nitric oxide synthase attenuates blood-brain barrier disruption during experimental meningitis, Brain Research, 720:75-83 (1996).							
	AG	microvasculati	Brandt, L., et al., Effects of topical application of calcium antagonist (nifedipine) on feline cortical pial microvasculature under normal conditions and in focal ischemia, Journal of Cerebral Blood Flow and Metabolism, 3:44-50 (1983).						
	АН		Brioni, J.D., et al., Activators of soluble guanylate cyclase for treatment of male erectile dysfunction, International Journal of Impotence Research, 14:8-14 (2002).				dysfunction, .		
	ΑI		Bychkov, R., et al. Calicum-activated potassium channels and nitrate-induced vasodilation in human coronary arteries, J Pharacol Exp Therap, 285:293-8 (1998). ABSTRACT ONLY.				on in human		
	AJ		Chandran, S., et al., <i>Nitric oxide: concepts, current perspectives and future therapeutic implications</i> , <u>Indian Journal of Pharmacology</u> , 30:351-366 (1998).				mplications, Indian		
	AK	Chi, O.Z., et al. Effect of inhibition of nitric oxide synthase on blood-brain barrier transport in focal cerebischemia, Pharmacologylogy, 48:367-373 (1994).				oort in focal cerebral			
	AL	Cloughesy, T.I	Cloughesy, T.F., et al., <i>Pharmacological blood-brain barrier modification for selective drug delivery</i> , Journal of Neuro-Oncology, 26:125-132 (1995).					lrug delivery, Journal	
	AM		Feelisch, M., The use of nitric oxide donors in pharmacological studies, Naunyn-Schmiedeberg's Arch Pharmcol, 358:113-122 (1998).						
	AN.	Fukao, M., et a	Fukao, M., et al., Cyclic GMP-dependent protein kindase activates cloned BKCa channels expressed in mammalian cells by direct phophorylation at serine 1072, J Biol Chem, 274(16):10927-35 (1999).						
	ÃO	Fukumura, D.,	Fukumura, D., et al., Role of nitric oxide in angiogenesis and microcirculation in tumors, Cancer and Metastasis Reviews, 17:77-89 (1998).						
	AP	He, P., et al., c	He, P., et al., cGMP modulates basal and activated microvessel permeability independenty of [Ca2+]i, Am J Physiol, 274:H1865-74 (1998). ABSTRACT ONLY.						
	AQ	Herrera, G.M., et al., Maintained vasodilatory response to cromakalim after inhibition of nitric oxide synthesis, J Cardiovasc Pharmacol, 31:921-9 (1998). ABSTRACT ONLY							
EXAMINE	R				D.A	ATE CONSID	ERED		1
		nitial if reference conside					P 609; Dra	w line through	citation if not in

LIST OF INFORMATION DISCLOSED BY APPLICANT (Use several sheets if necessary)

ATTY, DOCKET NO. 08143/105002		FILING DATE October 29, 2003		
APPLICANT		GROUP		
	Nagendra S. Ningaraj			
	OTHER REFERENCES (Including	g Author, Title, Date, Pertinent Pages, Etc.)		
AR	Holschermann, H., et al., Dual role of coendothelial cells, Am J Physiol, 272:H9	GMP in modulation of macromolecule permeability of aortic 1-8 (1997). ABSTRACT ONLY.		
AS	Hongli, X., et al., Opening blood-brain- malignant cerebral glioma, Chinese Me	barrier by intracarotid infusion of papaverine in treatment of dical Journal, 111(8):751-753 (1998).		
AT	Hurst, R.D., et al., <i>Nitric oxide-induced</i> <u>Journal of Cellular Physiology</u> , 167:89-9	perturbations in a cell culture model of the blood-brain barrier, 94 (1996).		
AU	Inamura, T., et al., Intracarotid histamir Neurological Research, 16:125-128 (199	ne infusion increases blood tumour permeability in RG2 glioma, 94).		
AV	Inamura, T., et al., Intracarotid infusion to brain tumors, J Neurosurg, 81:752-75	of RMP-7, a bradykinin analog: a method for selective drug delivery 8 (1994).		
AW	Janigro, D., et al., Regulation of blood-b 75:528-528 (1994).	rain barrier endothelial cells by nitric oxide, Circulation Research,		
AX	Kimura, M., et al., Responses of human Cardiovasc Pharmacol, 32: 695-701 (19	basilar and other isolated arteries to novel nitric oxide donors, <u>J</u> 98). ABSTRACT ONLY.		
AY	Koesling, D., Modulators of soluble gua	mylyl cyclase, Naunyn-Schmiedeberg's Arch Pharmacol, 358:123-126		
AZ	Liu, Y., et al., Repeated, short-term isch barrier in rats with RG2 glioma, Neurol	emia augments bradykinin-mediated opening of the blood-tumor ogical Research, 23:631-639 (2001).		
ВА	Lohse, M.J., et al., <i>Pharmacology of NO</i> 358:111-112 (1998).	D:cGMP signal transduction, Naunyn-Schmiedeberg's Arch Pharmcol,		
ВВ	Matskado, T., et al., Selective Increase in Brain Tumors, Acta Neurochir, 60: 403-	n Blood Tumor Permeability by Calcium Antagonists in Transplanted 405 (1994).		
BC	Mayer, B., et al., Nitric oxide synthases: Schmiedeberg's Arch Pharmcol, 358:12	catalytic function and progress toward selective inhibition, Naunyn-7-133 (1998).		
BD	Mayhan, W.G., Role of nitric oxide in hi Brain Research, 743:70-76 (1996).	stamine-induced increases in permeability of the blood-brain barrier,		
BE	Mayhan, W.G., et al., Glutamate-induce (1996).	d disruption of the blood-brain barrier in rats, <u>Stroke</u> , 27:965-970		
BF	Nakano, S., et al., <i>Increased brain micro</i> by nitric oxide, Cancer Research, 56:402	ovessel permeability after intracarotid bradykinin infusion is mediated 17-4031 (1996).		
BG	of Neurological Surgeons Annual Meetin	tive K+ channels in blood-brain tumor barrier permeability, Congressing, 50 th Anniversary Celebration, September 23-28, 2000, Henry B. io, Texas, ABSTRACT No. 4309, p. 215.		
EXAMINER	1	DATE CONSIDERED		
EXAMINER: Initial conformance and not c	if reference considered, whether or not citation considered. Include copy of this form with next of	is in conformance with MPEP 609; Draw line through citation if not in communication to applicant.		

LIST OF INFORMATION DISCLOSED BY APPLICANT (Use several sheets if necessary)

ATTY, DOCKET NO. 08143/105002		SERIAL NO.	FILING DATE October 29, 2003		
APPLICANT Keith L. Black and	Nagendra S. Nin	garaj	GROUP		
	OTHER	REFERENCES	(Including Author, Title, Date, Pertinent Pages, Etc.)		
ВН	Ningaraj, N.S., et al., Ca2+ -dependent K+ channels are a key regulatory of blood-brain tumor barrier permeability, <u>Congress of Neurological Surgeons Annual Meeting</u> , 50 th Anniversary Celebration, September 23-28, 2000, Henry B. Gonzalez Convention Center, San Antonio, Texas, ABSTRACT No.428, p. 219.				
BI	Ningaraj, N.S., et al., Nitric oxide donors increase blood-brain tumor barrier permeability via Kca channels, Society for Neuroscience, 30 th Annual Meeting, New Orleans, LA, November 4-9, 2000, 26 Part 1, p. 338, ABSTRACT No. 126.8.				
BJ	Pardrige, W., et al., Blood -brain barrier and new approaches to drug delivery, West J Med, 156:281-286 (1992).				
BK .	Robertson, B.E., et al., cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells, Am J Physiol, 265:C299-C303 (1993).				
BL	Sobey, C.G., et al., Inhibitory effect of 4-aminopyridine on responses of the basilar artery to nitric oxide, Br J Pharmacol, 126:1437-43 (1999). ABSTRACT ONLY.				
BM	Salom, J.B., et al., Relaxant effects of sodium nitroprusside and NONOates in rabbit basilar artery, Pharmacology, 57:79-97 (1998). ABSTRACT ONLY.				
BN	Salom, J.B., et al., Comparative relaxant effects of the NO donors sodium nitroprusside, DEA/NO and SPER/NO in rabbit carotid arteries, Gen Pharmacol, 32:75-59 (1999). ABSTRACT ONLY.				
delayed impairment of global ischem			f sodium nitroprusside and NONates in goat middle cerebral artery: nia-reperfusion, <u>Nitric Oxide</u> , 3:85-93 (1999). ABSTRACT ONLY.		
			dependent blood-brain barrier permeability alteration in the rat brain,).		
BQ	BQ Smolenski, A., et al., Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects, Naunyn-Schmiedeberg's Arch Pharmacol, 358:134-138.				
BR					
BS	Takayasu, M., et al., Effects of calcium antagonists on intracerebral penetrating arteriolesi in rats, <u>J. Neurosurg</u> , 69:104-109 (1988).				
BT	Uchida, M., et al., Overexpression of bradykinin type 2 receptors on glioma cells enhances bradykinin-mediated blood-brain tumor varrier permeability increase, Neurological Research, 24:739-745				
EXAMINER			DATE CONSIDERED		
EVAMINED: In:t:	al if rafarance cons	dared whether or no	ot ditation is in conformance with MDED 600: Drow line through ditation if not in		

conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. SERIAL NO. 08143/105002			FILING DATE October 29, 2003			
APPLICA Keith L		Nagendra S. Ningaraj	GROUP			
		OTHER REFERENCES (In	cluding Author, Title, Date, Pertinent Pages, Etc.)			
	BU	GMP-dependent protein kinase, (ependent blood-brain tumor barrier permeability is not mediated by cyclic Congress of Neurological Surgeons Annual Meeting, 50 th Anniversary 100, Henry B. Gonzalez Convention center, San Antonio, Texas, ABSTRACT			
	BV Vodovotz, Y., et al., Regulation of transforming growth factor beta 1 by nitric oxide, Cancer Res, 59:21-(1999). ABSTRACT ONLY.					
	BW	BW Yukabu, M.A., Hematoma-induced enhanced cerebral vasoconstriction to leukotriene C4 and endothelin-1 piglets: role of prostanoids, Pediatr Res, 38:119-23 (1995). ABSTRACT ONLY.				
: 1.	BX	Tocris Web Page, http://www.tocris.com/cat/nodonorstxt.html No Donors/Precursors, pp.1-2, Downloaded 5/31/00.				
	BY	Sigma-Aldrich Web page, http://vsearch.sial.com/search 97cgi/s97-cgi, p.1, downloaded 5/31/00.				
EXAMI	NER	*	DATE CONSIDERED			
EXAM	INER: Initia	al if reference considered, whether or not o	citation is in conformance with MPEP 609: Draw line through citation if not in			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.